# ASCT With TEAM Conditioning for Lymphoma With High Risk of CNS Relapse

> **NCT07481669** · PHASE2 · RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 45 (estimated)

## Conditions studied

- Lymphoma Patients With High-risk of Central Nervous System Relapse

## Interventions

- **DRUG:** TEAM regimen (thiotepa, etoposide, cytarabine and melphalan)

## Key facts

- **NCT ID:** NCT07481669
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2028-03-31
- **Final completion:** 2028-03-31
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07481669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07481669, "ASCT With TEAM Conditioning for Lymphoma With High Risk of CNS Relapse". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07481669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*